THANK YOU FOR SUBSCRIBING
bit-MAP®, bitBiome's proprietary microbe-focused single-cell genomic platform, will provide unprecedented insight on the link between oral and gut microbes and disease states.
Fremont, CA: bitBiome, an emerging leader in microbiome analytics, raised 700 million JPY (approx. $6.6m US) in Series B financing from previous and new investors, including The University of Tokyo Edge Capital Partners, Universal Materials Incubator, and other Japan-based venture capital firms. This new funding brings bitBiome's total equity financing to 1.05 billion yen (approx. $10m US). It will support the company's growth toward unlocking the vast untapped potential of microbes in various industries using bit-MAP®, a unique microbe-focused single-cell genomics platform.
bitBiome's bit-MAP system is a unique single-cell genomics platform for microbes, with a mission of unlocking microbes' potential. The company has increased through collaborative research with various corporate and academic partners.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
bitBiome has strengthened its business development, R&D, and administration divisions through new hires and CEO/COO participation, and built up its team. R&D and analytical capabilities were improved through the acquisition of lab facilities and equipment and bioinformatics capabilities. The maximum number of single cells analyzed per month was successfully expanded from 2,000 genomes to over 20,000 genomes. Additionally, eight international patent applications have been filed to reinforce the bit-MAP® system's technological superiority.
[vendor_logo_first]bitBiome's new capital will be used to accelerate growth in the following areas:
• In-house research to analyze the relationship between microbes and disease states
• Purchasing lab equipment (including a next-generation sequencer) to strengthen R&D capabilities and throughput further
• Acceleration of global business development
• Securing and maintaining intellectual property
• Talent acquisition
bitBiome will use the Series B financing to launch a large-scale study on patient stool and saliva samples for more than 20 diseases, including cancer, intestinal diseases, autoimmune diseases, and neuropsychiatric disorders. Patient samples will be obtained from patients registered on the panel in cooperation with QLife, a Japan-based clinical solution provider. For each disease, bitBiome will engage with partners for collaborative research towards novel drug or biomarker discovery, as well as access to the developed proprietary datasets.
See also: Top Genomics Solution Companies
More in News